Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Enanta Pharmaceuticals (ENTA) Leases (2019 - 2025)

Enanta Pharmaceuticals' Leases history spans 7 years, with the latest figure at $37.0 million for Q4 2025.

  • For Q4 2025, Leases fell 6.73% year-over-year to $37.0 million; the TTM value through Dec 2025 reached $37.0 million, down 6.73%, while the annual FY2025 figure was $37.5 million, 7.65% down from the prior year.
  • Leases reached $37.0 million in Q4 2025 per ENTA's latest filing, down from $37.5 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $41.2 million in Q2 2024 to a low of $4.7 million in Q3 2021.
  • Average Leases over 5 years is $26.1 million, with a median of $23.8 million recorded in 2022.
  • Peak YoY movement for Leases: crashed 32.89% in 2021, then surged 400.42% in 2022.
  • A 5-year view of Leases shows it stood at $18.8 million in 2021, then increased by 24.99% to $23.5 million in 2022, then decreased by 9.33% to $21.3 million in 2023, then surged by 85.88% to $39.7 million in 2024, then decreased by 6.73% to $37.0 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Leases are $37.0 million (Q4 2025), $37.5 million (Q3 2025), and $38.2 million (Q2 2025).